China channel feed

With clin­i­cal tri­als lined up for Zen­tal­is drugs, Chi­na's Zen­tera sets its sights on more deal­mak­ing and an IPO

4 years ago
Financing

BeiGene looks to carve out more space in the US mar­ket, set­ting up BTK drug for 2nd blood can­cer nod

4 years ago
R&D

Shoot­ing straight for Ven­clex­ta, a sea­soned Chi­nese CEO has glob­al dreams for his start­up

4 years ago
Financing

Chi­nese re­searcher — and for­mer 'fugi­tive' — re­turns home af­ter DOJ moves to drop a spate of cas­es

4 years ago
People

As health­care heats up on HKEX, Qim­ing sets up $500M fund ded­i­cat­ed to pub­lic com­pa­nies

4 years ago
Financing

Af­ter chim­ing in an­ti­body to Covid-19 fight, Jun­shi drops $30M to kick off mR­NA joint ven­ture in Chi­na

4 years ago
Deals

A No­var­tis castoff with a trou­bled past head­lines Chi­nese biotech's Hong Kong IPO quest

4 years ago
Financing

Chi­nese an­ti­body play­er chas­es Hong Kong IPO with lead Rit­ux­an chal­lenger ready for late-stage test

4 years ago
Financing

As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

4 years ago
Pharma

Dis­cov­ery by Shang­hai sci­en­tists in­spires new plan of AT­TEC for pro­tein degra­da­tion

4 years ago
Financing
Startups

Bap­tized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to car­ry on with pipeline for in­fec­tious dis­eases and be­yond

4 years ago
Financing

With Eli Lil­ly's back­ing, a team of Seagen vet­er­ans with ADC chops is look­ing to crash the Chi­nese on­col­o­gy par­ty

4 years ago
Financing

In search of a post-Tec­fidera hit for MS, Bio­gen fol­lows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of Chi­na

4 years ago
Deals

Chi­nese health au­thor­i­ty erects new gold stan­dard in on­col­o­gy R&D, spook­ing in­vestors in boom­ing field

5 years ago

Sir­naomics puts off an IPO a lit­tle longer as it pock­ets an­oth­er megaround. Is an S-1 around the cor­ner this time?

5 years ago
Financing

For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

5 years ago
Startups

Yescar­ta goes to Chi­na as Fo­s­un Kite nabs his­toric first CAR-T OK

5 years ago
Cell/Gene Tx
FDA+

Al­lo­gene, Over­land woo an ex­pe­ri­enced hand from WuXi to steer their al­lo­gene­ic CAR-T JV

5 years ago
People
Cell/Gene Tx

Hutchmed files for $600M+ IPO in Hong Kong as lead on­col­o­gy drug su­r­u­fa­tinib awaits FDA's good graces

5 years ago
Financing

Trail­ing the Big Phar­ma play­ers, a less­er known BC­MA CAR-T can­di­date comes in­to the spot­light

5 years ago
R&D
Cell/Gene Tx

No­vo Hold­ings, Vi­vo lead a record $200M raise for a Sin­ga­pore-based tools play­er with plans for a Boston hub, new deals

5 years ago
Financing
Outsourcing

Per­cep­tive's Chi­na up­start Lian­Bio con­tin­ues swing­ing deals, team­ing up with lead Xon­toge­ny biotech Lan­dos in IBD

5 years ago
Deals

Ki­nase in­hibitor spe­cial­ist Kin­nate launch­es Shang­hai sub­sidiary with $35M to mar­ket its pro­grams in Chi­na

5 years ago
Financing

Saman­tha Du's Quan Cap­i­tal, Lil­ly Asia back Chi­na's first big kid­ney play

5 years ago
Financing
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times